Healthcare & Biotech

SHERIDAN, WYOMING - May 10, 2026 - Fette Compacting has formally introduced its comprehensive R&D Solutions program, transitioning the company from a traditional equipment supplier to an integrated process partner for pharmaceutical manufacturers. The newly structured service framework supports drug developers from initial powder formulation through to validated commercial serial production. By embedding Quality by Design principles early in the development lifecycle, the initiative directly addresses the critical need to accelerate time-to-market and maximize effective patent exclusivity periods. This strategic realignment aims to eliminate isolated development steps, ensuring that complex critical material attributes are seamlessly aligned with final production parameters.

SHERIDAN, WYOMING - April 4, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

WASHINGTON, 4 March 2026: AdvaMed said the U.S. Senate has approved legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, and the association called on the House of Representatives to move quickly on passage. The medtech trade group said the vote matters because authorization for the two programs lapsed on 30 September 2025, leaving early-stage medical technology companies without the certainty they need as they pursue product research and development.

SHERIDAN, WYOMING - March 21, 2026 - HubSpot has published a new guide comparing Claude and ChatGPT for marketers, focusing on three practical buying criteria: pricing, integrations, and use cases. The article frames AI model selection as an operational decision rather than a purely technical one, aimed at helping marketing teams choose the right large language model for day-to-day work. For business users, that matters because LLM choice can affect tool compatibility, workflow design, and budget planning across content and campaign functions.

SHERIDAN, WYOMING - March 31, 2026 - Early-stage medtech companies could regain a key non-dilutive funding route in 2026 after the Senate passed legislation to reauthorize the federal Small Business Innovation Research and Small Business Technology Transfer programs, reducing uncertainty that has persisted since the programs' authorization lapsed on September 30, 2025. AdvaMed said the Senate action restores momentum for grants that support early research and development at startups and small manufacturers, and it urged the House of Representatives to move quickly on passage. The association framed the programs as an important bridge for companies that struggle to finance next-generation device development before products reach patients or later-stage commercial milestones.

SHERIDAN, WYOMING - March 31, 2026 - Health organizations planning 2026 research participation in Europe gain a new route to influence project design, allocate in-kind resources, and support proposals without taking on full private-member status in the Innovative Health Initiative. MedTech Europe points to an 11 February 2026 webinar hosted by the IHI Office, focused on the contributing partner category for organizations that are not affiliated with an IHI private industry member, as well as organizations affiliated with a private member that need to understand how contributing partners can support proposals. The session is positioned around practical participation questions rather than broad program promotion, including eligibility, application steps, contribution rules, and common mistakes.

SHERIDAN, WYOMING - March 31, 2026 - European hospitals evaluating 2026 imaging, intervention, and workforce plans now have a new validation pathway for AI-assisted neurovascular and oncology procedures as the SHERPA consortium starts seven clinical studies focused on workflow automation, precision support, and staff-pressure reduction in minimally invasive care. The four-year project has a total budget of EUR 21.5 million, is coordinated by Philips, and is co-funded by the EU Innovative Health Initiative and industry partners. Its work targets minimally invasive treatment workflows for brain aneurysms, liver tumors, and lung biopsy settings where specialized expertise is limited and procedure complexity is high.

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

SHERIDAN, WYOMING - December 30, 2025 - ALS Northwest says it increased its financial investment in ALS research throughout 2025, expanding support for new approaches in treatment, prevention, and scientific understanding while joining a multi-organization funding initiative intended to strengthen the overall research pipeline.

Research investment strategy and portfolio focus

ALS Northwest framed its 2025 approach as a scaled-up commitment to research designed to accelerate innovation in amyotrophic lateral sclerosis (ALS). The organization said its efforts span multiple stages of scientific discovery, with an emphasis on enabling new approaches that could move the field forward. For research stakeholders, the operational question is not only how much is invested, but how efficiently funding is converted into validated findings, new targets, and ultimately clinical progress.

SHERIDAN, WYOMING - December 19, 2025 - Eli Lilly's experimental daily oral obesity medicine orforglipron posted Phase III data suggesting it can help patients maintain weight loss after long-term treatment with injectable GLP-1 therapies-an outcome with direct implications for adherence, payer strategy, and competition with Novo Nordisk's coming oral semaglutide filing.